Merck & Company, Inc.

• MRK Stock Price 24h change: +2.54%. From 108.26 USD to 111.01 USD. (The gain was driven by analyst price-target increases and continued speculation regarding a potential $32 billion acquisition of Revolution Medicines).
• From a technical perspective, the stock is showing "sustained bullish momentum," trading above its 50-day ($100.62) and 200-day ($89.53) moving averages. Immediate resistance is noted at $112, near its 52-week high, while support is firmly established around the $108 level.
• Merck is reportedly in advanced talks to acquire cancer drugmaker Revolution Medicines (RVMD) for up to $32 billion to bolster its oncology pipeline ahead of the 2028 Keytruda patent cliff.
• Analysts at UBS and Goldman Sachs recently raised their price targets for MRK to $130 and $120 respectively, citing strong profitability and a successful quarterly dividend increase to $0.85 per share.
• Merck's Cidara Therapeutics tender-offer deadline is approaching next week, following a $9.2 billion merger deal that saw Cidara shares rocket earlier in the year.
• At the J.P. Morgan Healthcare Conference, AbbVie (ABBV) and Novo Nordisk outlined aggressive 2026 growth strategies, focusing on "consumer-style" obesity markets and defense of key immunology franchises.
• The U.S. pharmaceutical sector is facing renewed policy uncertainty as "Most Favored Nation" drug pricing debates return, alongside potential shifts in federal vaccine recommendation authorities.

• MRK Stock Price 24h change: -0.85%. From 109.19 USD to 108.26 USD.
The price declined slightly as the market digested recent acquisition rumors and long-term revenue targets presented at the J.P. Morgan Healthcare Conference.

• From a technical perspective, MRK exhibits a "bullish momentum in a consolidation phase": the stock is trading near its 52-week high ($112.90) with an RSI reflecting a healthy bullish sentiment. While short-term volatility persists due to M&A speculation, the long-term support remains firm around the $105 level, supported by strong moving average cross-overs.

• Merck is reportedly in advanced talks to acquire cancer-drug biotech Revolution Medicines (RVMD) in a deal that could be valued at approximately $30 billion, aiming to bolster its oncology pipeline ahead of Keytruda's 2028 patent cliff.

• During the J.P. Morgan Healthcare Conference, Merck management raised its mid-2030s revenue target to $70 billion, highlighting new growth drivers including the recently acquired influenza candidate MK-1406 and next-gen oncology treatments.

• UBS reiterated a Buy rating on MRK with a $130 price target, citing high confidence in the potential of its Sac-TMT treatment and upcoming Phase III data readouts expected throughout 2026.

• AbbVie announced a landmark $100 billion pledge toward U.S. production and R&D as part of a drug pricing deal, signaling a shifting regulatory landscape for major pharmaceutical players in 2026.

• The FDA qualified its first AI-based tool, AIM-NASH, to accelerate clinical trials for liver disease, marking a significant step in the industry-wide adoption of AI to reduce drug development timelines and costs.